192 related articles for article (PubMed ID: 35883440)
1. In Silico Discovery and Optimisation of a Novel Structural Class of Hsp90 C-Terminal Domain Inhibitors.
Zajec Ž; Dernovšek J; Gobec M; Tomašič T
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883440
[TBL] [Abstract][Full Text] [Related]
2. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma.
Zajec Ž; Dernovšek J; Distel M; Gobec M; Tomašič T
Bioorg Chem; 2023 Feb; 131():106311. PubMed ID: 36495678
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors.
Shao LD; Su J; Ye B; Liu JX; Zuo ZL; Li Y; Wang YY; Xia C; Zhao QS
J Med Chem; 2017 Nov; 60(21):9053-9066. PubMed ID: 29019670
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationships of Benzothiazole-Based Hsp90 C-Terminal-Domain Inhibitors.
Dernovšek J; Zajec Ž; Durcik M; Mašič LP; Gobec M; Zidar N; Tomašič T
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452244
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-
Liu Y; Li C; Li Y; Zhang S; Zhang N; Bian X; Tan S
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290912. PubMed ID: 38083866
[TBL] [Abstract][Full Text] [Related]
8. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding.
Mak OW; Sharma N; Reynisson J; Leung IKH
Bioorg Med Chem Lett; 2021 Apr; 38():127857. PubMed ID: 33609661
[TBL] [Abstract][Full Text] [Related]
10. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
[TBL] [Abstract][Full Text] [Related]
12. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
16. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
18. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
